Vergelijking
IGF-1 LR3 vs. Ipamorelin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Groei
Groei
CAS-nr.
143045-27-6
170851-70-4
Molecuulmassa
9117.6 g/mol
711.86 g/mol
Halfwaardetijd
21 h
2 h
Sequentie
MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSAAib-His-D-2-Nal-D-Phe-Lys-NH2Werkingsmechanisme
IGF-1 LR3
IGF-1 LR3 is a recombinantly produced variant of human IGF-1. Two changes define its properties: (1) at position 3, glutamic acid is replaced by arginine; (2) a 13-amino-acid sequence is added at the N-terminus ('Long'). Both modifications drastically reduce affinity for the six IGF-binding proteins (IGFBP-1 to -6) that normally bind native IGF-1 in the blood and regulate its availability at the receptor. As a result, a larger fraction of the molecule is freely available to bind the type-1 IGF receptor (IGF-1R) — the same receptor as native IGF-1. In preclinical models and cell culture, LR3 IGF-1 therefore acts as a more potent agonist than unmodified IGF-1. The downstream signalling pathway (PI3K/Akt and MAPK) is identical to that of IGF-1; the modification changes bioavailability, not the receptor target.
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Bewijsbasis
Hoogste bewijs
Diermodel
Humane RCT
Studies
4
4
waarvan bij mensen
0
3
Geregistreerde effecten
4
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between IGF-1 LR3 and Ipamorelin?
- IGF-1 LR3 is classified as "Groei", while Ipamorelin is classified as "Groei". IGF-1 LR3: Synthetic analogue of insulin-like growth factor 1 (IGF-1) carrying an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications lower binding to IGF-binding proteins and extend its duration of action relative to native IGF-1. LR3 IGF-1 is primarily an established cell-culture reagent (serum-free media, bioprocessing); it is NOT an approved human medicine. Use in the bodybuilding grey market is described; as an IGF-1 analogue, LR3 IGF-1 falls under the WADA anti-doping prohibition. Ipamorelin: Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; clinical development was discontinued after phase 2 (post-operative ileus). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, IGF-1 LR3 or Ipamorelin?
- The highest available evidence level is "Diermodel" for IGF-1 LR3 and "Humane RCT" for Ipamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of IGF-1 LR3 and Ipamorelin in Germany and the United States?
- Duitsland: IGF-1 LR3 — Niet goedgekeurd, Ipamorelin — Niet goedgekeurd. Verenigde Staten: IGF-1 LR3 — Niet goedgekeurd, Ipamorelin — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.